Cummins, Inc. Debuts Combined Drivetrain for Defense Applications

Cummins, Inc. Debuts Combined Drivetrain for Defense Applications

Cummins-Meritor Drivetrain Components Featured at AUSA

COLUMBUS, Ind.–(BUSINESS WIRE)–
Today, Cummins Inc. (NYSE: CMI) announced the unveiling of its first combined solution to leverage solutions from its Cummins-Meritor portfolio engineered specifically for the demands of wheeled defense vehicles. This proof-of-concept drivetrain will be unveiled at the 2024 Annual AUSA Conference in Washington, DC, October 9-11.

Leveraging the strengths of several existing Cummins’ product lines to demonstrate Cummins’ ability to offer a complete vehicle powertrain, this innovative display features the Cummins L9 engine, Eaton-Cummins Endurant XD Pro transmission and Cummins-Meritor’s ProTec 4000 Series ISAS, ProTec 5000 Series tandem axles, RPL Drivelines, and MTC-3208 transfer case.

“Cummins’ portfolio of defense solutions has been bolstered by the addition of the Cummins-Meritor ProTec brand of drivetrain components,” said Jim Keane, Cummins Inc. Executive Director, Global Product Solutions for the Cummins-Meritor business unit. “Meritor Defense, now Cummins-Meritor, has a storied history of serving the defense market since the early 1900s. This legacy has long established these solutions as the leading drivetrain components available to defense applications. Combined with Cummins’ equally historic presence as the leading power supplier in the industry, we’re now able to offer our customers the most comprehensive portfolio of power generation and power distribution solutions available.”

Also featuring displays from Cummins’ Engine business unit, including both the Advance Combat Engine (ACE) and V903 engines, and the Power Generation business unit’s Tactical Energy Storage System (TESS), the Cummins booth will demonstrate a new commitment to being much more than a traditional ICE supplier.

Visit the Cummins team at the 2024 AUSA Annual Conference in booth #6619 or visit www.cummins.com or www.meritor.com to learn more.

About Cummins Inc.

Cummins Inc., a global power leader, is a corporation of complementary business segments that design, manufacture, distribute and service a broad portfolio of power solutions. The company’s products range from diesel, natural gas, electric and hybrid powertrains and powertrain-related components including filtration, aftertreatment, turbochargers, fuel systems, controls systems, air handling systems, automated transmissions, axles, drivelines, brakes, suspension systems, electric power generation systems, batteries, electrified power systems, electric powertrains, hydrogen production and fuel cell products. Headquartered in Columbus, Indiana (U.S.), since its founding in 1919, Cummins employs approximately 73,600 people committed to powering a more prosperous world through three global corporate responsibility priorities critical to healthy communities: education, environment and equality of opportunity. Cummins serves its customers online, through a network of company-owned and independent distributor locations, and through thousands of dealer locations worldwide and earned about $2.2 billion on sales of $28.1 billion in 2022. See how Cummins is powering a world that’s always on by accessing news releases and more information at https://www.cummins.com.

Forward-looking disclosure statement

Information provided in this release that is not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our forecasts, guidance, preliminary results, expectations, hopes, beliefs and intentions on strategies regarding the future. These forward-looking statements include, without limitation, statements relating to our plans and expectations for our revenues and EBITDA. Our actual future results could differ materially from those projected in such forward-looking statements because of a number of factors, including, but not limited to: any adverse results of our internal review into our emissions certification process and compliance with emission standards; increased scrutiny from regulatory agencies, as well as unpredictability in the adoption, implementation and enforcement of emission standards around the world; changes in international, national and regional trade laws, regulations and policies; changes in taxation; global legal and ethical compliance costs and risks; evolving environmental and climate change legislation and regulatory initiatives; future bans or limitations on the use of diesel-powered products; failure to successfully integrate and / or failure to fully realize all of the anticipated benefits of the acquisition of Meritor, Inc.; raw material, transportation and labor price fluctuations and supply shortages; any adverse effects of the conflict between Russia and Ukraine and the global response (including government bans or restrictions on doing business in Russia); aligning our capacity and production with our demand; the actions of, and income from, joint ventures and other investees that we do not directly control; large truck manufacturers’ and original equipment manufacturers’ customers discontinuing outsourcing their engine supply needs or experiencing financial distress, or change in control; product recalls; variability in material and commodity costs; the development of new technologies that reduce demand for our current products and services; lower than expected acceptance of new or existing products or services; product liability claims; our sales mix of products; failure to complete, adverse results from or failure to realize the expected benefits of the separation of our filtration business; our plan to reposition our portfolio of product offerings through exploration of strategic acquisitions and divestitures and related uncertainties of entering such transactions; increasing interest rates; challenging markets for talent and ability to attract, develop and retain key personnel; climate change, global warming, more stringent climate change regulations, accords, mitigation efforts, greenhouse gas (GHG) regulations or other legislation designed to address climate change; exposure to potential security breaches or other disruptions to our information technology environment and data security; political, economic and other risks from operations in numerous countries including political, economic and social uncertainty and the evolving globalization of our business; competitor activity; increasing competition, including increased global competition among our customers in emerging markets; failure to meet environmental, social and governance (ESG) expectations or standards, or achieve our ESG goals; labor relations or work stoppages; foreign currency exchange rate changes; the performance of our pension plan assets and volatility of discount rates; the price and availability of energy; continued availability of financing, financial instruments and financial resources in the amounts, at the times and on the terms required to support our future business; and other risks detailed from time to time in our SEC filings, including particularly in the Risk Factors section of our 2022 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the SEC, which are available at http://www.sec.gov or at http://www.cummins.com in the Investor Relations section of our website.

Jon Mills

Director, External Communications

317-658-4540

[email protected]

KEYWORDS: Indiana United States North America

INDUSTRY KEYWORDS: Automotive Manufacturing Manufacturing Defense Other Defense Engineering

MEDIA:

Extreme Networks Schedules First Quarter Fiscal 2024 Financial Results Conference Call

Extreme Networks Schedules First Quarter Fiscal 2024 Financial Results Conference Call

MORRISVILLE, N.C.–(BUSINESS WIRE)–Extreme Networks, Inc. (Nasdaq: EXTR), a leader in cloud networking, today announced plans to release financial results for its first fiscal quarter, ended September 30, 2023. The company will announce before market open on Wednesday, November 1, 2023, followed by an earnings conference call and webcast at 8:00 a.m. ET.

The details for the webcast are:

When:

Wednesday, November 1 at 8:00 a.m. ET (5:00 a.m. PT)

Where:

http://investor.extremenetworks.com/

Dial in:

To access the call by phone, please go to this link (Registration Link) and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time.

Q&A Participation:

 

 

If you would like to participate in the Q&A, please register here: Registration Link [Q&A]

About Extreme Networks:

Extreme Networks, Inc. (EXTR) is a leader in cloud networking focused on delivering services that connect devices, applications, and people in new ways. We push the boundaries of technology leveraging the powers of machine learning, artificial intelligence, analytics, and automation. 50,000 customers globally trust our end-to-end, cloud-driven networking solutions and rely on our top-rated services and support to accelerate their digital transformation efforts and deliver progress like never before. For more information, visit Extreme’s website at https://www.extremenetworks.com or follow us on LinkedIn, YouTube, Twitter, Facebook or Instagram.

Extreme Networks and the Extreme Networks logo are trademarks or registered trademarks of Extreme Networks, Inc. in the United States and other countries.

Investor Relations and Press Contacts:

Stan Kovler

Vice President, Corporate Strategy & Investor Relations

Extreme Networks

919-595-4196

[email protected]

Amy Aylward

Vice President, Corporate Marketing

Extreme Networks

603-952-5138

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Technology Networks Internet

MEDIA:

Logo
Logo

Extreme Networks 2023 Investor Day Returns to Major League Baseball Headquarters in New York City

Extreme Networks 2023 Investor Day Returns to Major League Baseball Headquarters in New York City

MORRISVILLE, N.C.–(BUSINESS WIRE)–Extreme Networks, Inc. (Nasdaq: EXTR), a leader in cloud networking, today announced that it will host its second in-person Investor Day of 2023 on Tuesday, Nov. 7 at the headquarters of Major League Baseball (MLB) in New York City. The in-person event will begin promptly at 8:30 a.m. ET and will also be livestreamed for virtual attendees.

Extreme’s Investor Day will include executive presentations, featured customer guests, and opportunities to speak in-person with Extreme’s leadership team. Question and answer sessions will follow each presentation.

Topics covered will include:

  • Why customers and partners choose Extreme

  • Strategic growth opportunities

  • Customer and partner testimonials

  • Go-to-market developments and expansion plans

  • Financial outlook and long-term goals

Registration:

For more information and to register for the in-person or livestreamed event, visit: https://cvent.me/kxXbGK?RefId=PR

About Extreme Networks:

Extreme Networks, Inc. (EXTR) is a leader in cloud networking focused on delivering services that connect devices, applications, and people in new ways. We push the boundaries of technology leveraging the powers of machine learning, artificial intelligence, analytics, and automation. Over 50,000 customers globally trust our end-to-end, cloud-driven networking solutions and rely on our top-rated services and support to accelerate their digital transformation efforts and deliver progress like never before. For more information, visit Extreme’s website at https://www.extremenetworks.com/ or LinkedIn, YouTube, Twitter, Facebook or Instagram.

Extreme Networks and the Extreme Networks logo are trademarks or registered trademarks of Extreme Networks, Inc. in the United States and other countries.

Investor Relations and Press Contacts:

Stan Kovler

Vice President, Corporate Strategy & Investor Relations

Extreme Networks

919-595-4196

[email protected]

Amy Aylward

Vice President, External Communications

Extreme Networks

603-952-5138

[email protected]

KEYWORDS: United States North America North Carolina California New York

INDUSTRY KEYWORDS: Data Management Apps/Applications Technology Networks Artificial Intelligence Internet

MEDIA:

Logo
Logo

Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®

In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions

Presentation to be made at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual Meeting

NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of APP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device with late-stage product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that it will deliver a presentation on the microbial integrity of its Optejet dispensing device at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual Meeting, which is being held October 11-14, 2023.

“Recent studies of both preserved and preservative-free multi-use eye drops have shown contamination rates as high as 94%, suggesting that there is an urgent need for a next-generation topical ophthalmic drug dispensing device that can administer medication without preservatives or contaminants, both of which can be harmful to the eye,” stated Michael Rowe, chief executive officer of Eyenovia. “This study successfully demonstrates the Optejet’s ability to maintain product sterility even when exposed to a microbial load that exceeds typical environmental conditions, supporting the potential for the Optejet to be used to deliver preservative-free medications, which would confer significant long-term benefits to patients.”

Presentation details:
Title:
Demonstration of Microbial Integrity for a Multi-Dose Ophthalmic Spray Drug Device
Date: Thursday, October 12, 2023
Time: 4:30-6:30pm CT (5:30-7:30pm ET)
Location: Exhibit Hall D, New Orleans Ernest N. Morial Convention Center
Poster #: 36
   

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. Eyenovia is currently focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis.

In addition to commercializing Mydcombi, in August 2023, Eyenovia acquired the U.S. commercial rights to APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) from Formosa Pharmaceuticals. APP13007, which is currently under review by the FDA, is a potent steroid being developed to reduce pain and inflammation following ocular surgery. The agency has assigned a Prescription Drug User Fee Act (PDUFA) action date for APP13007 of March 4, 2024.

Eyenovia is also advancing late-stage development of medications in the Optejet device for presbyopia and myopia progression (partnered with Bausch+Lomb in the U.S. and Canada and Arctic Vision in China and South Korea).

For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT SAFETY INFORMATION for MYDCOMBI

 (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%

Forward-Looking Statements

Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology, and the potential for approval of APP13007. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position.

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:

Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
[email protected]

Eyenovia Investor Contact:

Eric Ribner
LifeSci Advisors, LLC
[email protected]
(646) 751-4363

Eyenovia Media Contact:

Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
[email protected]



Plus Therapeutics to Participate in the Jones Trading Healthcare Summit and ThinkEquity Conference in October

AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that company management will attend and hold one-on-one investor meetings at the upcoming Jones Trading 2023 Healthcare Summit being held October 9-11, 2023 in Miami, FL. Marc H. Hedrick, M.D., President and Chief Executive Officer, will also present and hold one-on-one investor meetings at the upcoming ThinkEquity Conference being held on October 19, 2023 in New York, NY.

Jones Trading 2023 Healthcare Summit – October 9-11, 2023

Format:        One-on-one investor meetings

Location:      Eden Roc Miami Beach, Miami Beach, FL

Link:              Register here

ThinkEquity Conference – October 19, 2023

Format:         Corporate Presentation

Date/Time:    Thursday, October 19, 2023 at 12:30-1:00pm ET

Participant:    Marc H. Hedrick, M.D., President & CEO, Plus Therapeutics

Location:        Mandarin Oriental, New York

Webcast:        Register here

Please contact your Jones or ThinkEquity representative to schedule one-on-one meetings with the management team during the conferences.

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a robust supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186Re including the ability of 186Re to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186Re; the continued evaluation of 186Re including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends, or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact

Corey Davis, Ph.D.
LifeSci Advisors
(212) 915-2577
[email protected]

 



Mercury to Bring Raytheon’s Advanced Cyber Resiliency and Intrusion Detection Tools to the Mercury Processing Platform

ANDOVER, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a technology company that delivers processing power for the most demanding aerospace and defense missions, today announced it is working with Raytheon, an RTX business, to increase survivability and resiliency of its mission-critical solutions by incorporating Raytheon’s advanced cyber resiliency and intrusion detection tools into Mercury’s processing platform.

As threats against critical systems continue to grow in scope and sophistication, Mercury and Raytheon recognize the need for significantly stronger security controls to protect mission-critical systems, and both are dedicated to delivering comprehensive and resilient protection solutions to maintain mission effectiveness in cyber-contested environments.

Through this relationship, Mercury gains the ability to integrate Raytheon’s Electronic Armor and CADS products into its portfolio of mission systems, including secure mission processors, communication management units, rugged servers, communication management units, and data recorders. Raytheon’s cybersecurity tools complement Mercury’s BuiltSECURE technology that protects critical data with industry-leading physical security, cryptography, and secure boot features. Mercury and Raytheon are industry leaders in building and securing high-performance, open-architecture products and subsystems for the aerospace and defense industry, including SOSA-aligned mission computers. Their combined offerings provide aerospace and defense programs with an effective approach to addressing emerging cyber survivability endorsement requirements, which are focused on preventing, detecting, responding, and recovering from cyberattacks.

Electronic Armor is a cyber resiliency solution that prevents reverse engineering and protects the confidentiality and integrity of data, as well as applications from attackers who have bypassed traditional information assurance controls and/or gained escalated privilege on a system. Among its many features is the hardening of the operating system, providing data-at-rest and runtime protections, preventing execution of unauthorized applications, and preventing modification/introspection of sensitive applications and data.

CADS is a real-time Intrusion Detection System (IDS) for the standard control buses found in airframes and ground vehicles. CADS provides cyber anomaly detection and complete bus traffic logging for mission- and safety-critical systems. It heightens situational awareness for platform operators and support teams and includes offline analysis tools to provide long-term performance and cross-fleet analysis of cyber trends.

To learn more about how Raytheon’s Electronic Armor and CADS solutions can integrate with Mercury hardware, visit the Mercury booth (#1439) at this week’s AUSA Annual Meeting and Exposition.

Mercury Systems – Innovation that matters®

Mercury Systems is a technology company that pushes processing power to the tactical edge, making the latest commercial technologies profoundly more accessible for today’s most challenging aerospace and defense missions. From silicon to system scale, Mercury enables customers to accelerate innovation and turn data into decision superiority. Mercury is headquartered in Andover, Massachusetts, and has 24 locations worldwide. To learn more, visit mrcy.com. (Nasdaq: MRCY)

Forward-Looking Safe Harbor Statement

This press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s focus on enhanced execution of the Company’s strategic plan under a refreshed Board and leadership team. You can identify these statements by the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, continued funding of defense programs, the timing and amounts of such funding, general economic and business conditions, including unforeseen weakness in the Company’s markets, effects of any U.S. federal government shutdown or extended continuing resolution, effects of geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in or cost increases related to completing development, engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in, or in the U.S. government’s interpretation of, federal export control or procurement rules and regulations, changes in, or in the interpretation or enforcement of, environmental rules and regulations, market acceptance of the Company’s products, shortages in or delays in receiving components, supply chain delays or volatility for critical components such as semiconductors, production delays or unanticipated expenses including due to quality issues or manufacturing execution issues, failure to achieve or maintain manufacturing quality certifications, such as AS9100, the impact of the COVID pandemic and supply chain disruption, inflation and labor shortages, among other things, on program execution and the resulting effect on customer satisfaction, inability to fully realize the expected benefits from acquisitions, restructurings, and execution excellence initiatives or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, effects of shareholder activism, increases in interest rates, changes to industrial security and cyber-security regulations and requirements and impacts from any cyber or insider threat events, changes in tax rates or tax regulations, such as the deductibility of internal research and development, changes to interest rate swaps or other cash flow hedging arrangements, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, which difficulties may be impacted by the termination of the Company’s announced strategic review initiative, unanticipated challenges with the transition of the Company’s Chief Executive Officer and Chief Financial Officer roles, including any dispute arising with the former CEO over his resignation, unanticipated costs under fixed-price service and system integration engagements, and various other factors beyond our control. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 30, 2023 and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward looking statement to reflect events or circumstances after the date on which such statement is made.

INVESTOR CONTACT

Nelson Erickson
Senior Vice President, Strategy and Corporate Development
[email protected]

MEDIA CONTACT

Turner Brinton
Sr. Director, Corporate Communications
[email protected] 



OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)


  • OKYO plans to initiate a 40-patient OK-101 open-label clinical trial in Q1 2024 with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCP.

  • Second clinical indication for OK-101 which is currently in 240-patient Phase 2 clinical trial to treat dry eye disease, with top-line data anticipated in December 2023.

LONDON and NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory dry eye disease (“DED”), a multi-billion-dollar market, and for neuropathic corneal pain, a severe ocular condition with no FDA approved therapy, today announced that it filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA.

NCP remains a major unmet medical need for the ocular community, as there is no FDA-approved drug to treat NCP and this trial provides the opportunity to establish OK-101’s potential to treat this condition. The open-label trial will provide an opportunity to evaluate the safety and efficacy of OK-101 for NCP in a real-world clinical setting, fostering a better understanding of its potential benefits for patients.

The NCP trial will be led by Pedram Hamrah, MD, Professor and Vice Chair of Research and Academic Programs, Co-Director of the Cornea Service and Director of the Center for Translational Ocular Immunology at Tufts Medical Center. An ophthalmologist and a clinician-scientist, Dr. Hamrah is a leading expert in NCP and co-inventor on the OK-101 patent. He is a member of OKYO’s Scientific Advisory Board and plans to serve as Principal Investigator of the study, which will be conducted at Tufts Medical Center.

“NCP, which can exhibit as a severe, chronic or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion,” said Dr. Hamrah. “However, there are no approved commercial treatments currently available for this condition, and consequently we are looking forward to initiating the clinical trial to investigate the potential efficacy of OK-101 to treat symptoms of NCP.”

“We are excited about OK-101’s dual combination of anti-inflammatory ocular activity and NCP reducing activity and are eager to evaluate this drug to treat NCP while awaiting the top-line data for OK-101 from the ongoing Phase 2 DED trial which is planned for released in December 2023,” said Dr. Gary S. Jacob, CEO of OKYO.

About OK-101

OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 is currently in a Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.

About the OK-101 Phase 2 DED Trial Design

This phase 2, multi-center, randomized, double–blinded, placebo-controlled study is designed to enroll approximately 240 subjects with DED who are being randomly divided into 3 cohorts of 80 patients. Participants are being selected based on specific inclusion and exclusion criteria. The three cohorts include one cohort treated with placebo, a second cohort treated with 0.05% OK-101, and the third cohort receiving 0.1% OK-101. The drug and placebo, respectively, are being administered in both eyes twice daily for 12 weeks. The duration of a patient’s treatment is approximately 14 weeks, including a 2-week run-in period, to address the placebo effect, which is common for trials involving a pain component, followed by 12 weeks of treatment. The protocol for the study includes two prespecified primary endpoints and a number of secondary endpoints. Further details regarding the specifics of the trial are posted on the clinicaltrials.gov public website (clinicaltrials.gov Identifier: NCT05759208 or https://clinicaltrials.gov/ct2/results?term=Okyo&cond=Dry+Eye+Syndromes).

About OKYO

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of inflammatory DED) and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. OKYO presently has a 240-patient phase 2 trial of OK-101 underway to treat patients with DED, and also has plans underway for the opening of a 40-patient trial of OK-101 to treat NCP in patients with this debilitating condition. For further information, please visit www.okyopharma.com.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements, including with respect to the anticipated timing of completion of enrolment of the Company’s Phase 2 trial of topical ocular OK-101 to treat DED and the release of top-line data therefrom. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further information, please visit the Company’s website at www.okyopharma.com
The person who arranged for the release of this announcement on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.

Enquiries:

OKYO Pharma Limited Gary S. Jacob, Chief Executive Officer U.S. 917-497-7560

Investor Relations Paul Spencer +44 (0)20 7495 2379



PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA.

American College of Surgeons Clinical Congress 2023

Presentation Title:  Impact of Locally Applied Doxycycline-Eluting Drug (D-PLEX) on Incisional Infection Rate in Elective Colorectal Surgery: A Phase 3, Prospective, Randomized, Double-Blind, Multicenter, and Multinational Clinical Trial
Presenter: Shmuel Sharoni, M.D.
Date/Time: October 23, 2023/4:15 PM – 5:45 PM Eastern Time
Location: Session SF120 – Colon and Rectal Surgery I
BCEC Ballroom East, Level 3

The abstract will be available on www.polypid.com once the conference concludes.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:

PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
[email protected]

Investors:

Brian Ritchie
LifeSci Advisors
212-915-2578
[email protected]



Polestar Day to Feature Future Technologies and Full Model Line-Up in Los Angeles on November 9

Polestar Day to Feature Future Technologies and Full Model Line-Up in Los Angeles on November 9

GOTHENBURG, Sweden–(BUSINESS WIRE)–
Polestar (Nasdaq: PSNY), the Swedish electric performance car brand, invites shareholders to attend an exclusive, in-person event on 9 November 2023 in Los Angeles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231009685596/en/

(Photo: Business Wire)

(Photo: Business Wire)

Polestar Day will provide an opportunity for participants to experience the latest innovations and technologies that are being integrated into Polestar’s growing line-up of design-led, luxury, performance EVs.

Management will be joined by select strategic partners in a keynote presentation, to share how collaboration is shaping Polestar’s electric performance cars, now and in the future.

Shareholders who would like to join the event can register their interest by completing the registration form available on https://investors.polestar.com/polestar-day. Spaces are limited and will be allocated on a first come, first served basis. Recent brokerage statement evidencing share ownership will need to be provided before attendance confirmation.

Bojana Flint

Head of Investor Relations

[email protected]

Theo Kjellberg

Head of Corporate PR

[email protected]

Tanya Ridd

Global Head of Communications & PR

[email protected]

KEYWORDS: Europe Sweden United States North America California

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Automotive Manufacturing Manufacturing General Automotive Automotive

MEDIA:

Logo
Logo
Photo
Photo
(Photo: Business Wire)

One Energy Energizes the Largest Electric Semi-Truck Charging Site in US at 30 MW Megawatt Hub Site in Ohio

One Energy Energizes the Largest Electric Semi-Truck Charging Site in US at 30 MW Megawatt Hub Site in Ohio

Innovative Customer-Specific Power Island™ Configuration to Serve Multiple Fleet Operators

FINDLAY, Ohio–(BUSINESS WIRE)–
One Energy Enterprises Inc. (“One Energy”), has unveiled the initial configuration and energization of its 30 megawatt (MW) electric semi-truck fleet charging site, located at its first Megawatt Hub in Findlay, Ohio. The company’s innovative Power Island™ concept demonstrates how One Energy plans to configure electric semi-truck charging infrastructure to concurrently support multiple corporate trucking fleet operators.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231009589668/en/

One Energy’s Megawatt Hub can deliver 760,000 kWh of capacity, powering up to 90 electric semi-trucks per day (Photo: Business Wire)

One Energy’s Megawatt Hub can deliver 760,000 kWh of capacity, powering up to 90 electric semi-trucks per day (Photo: Business Wire)

The Findlay Megawatt Hub is the largest constructed or publicly announced truck charging site in the United States in terms of available charging capacity. The site power system can accommodate up to 30 MW of charging in today’s configuration.

One Energy plans to utilize a radial charging configuration to optimize overall site efficiency, allowing multiple corporate customers to customize charging operations and equipment to their specific fleet’s needs. The site currently has fully functional capacity at medium and low voltages. One Energy has developed patent-pending physical systems to optimize its radial truck charging configuration and is working with charging equipment manufacturers to be ready to deploy both multiplatform and OEM-specific charging solutions that match individual truck needs and charging rates as the trucks are sold.

A new concept video showcasing the Power Island™ configuration by One Energy is embedded into this press release and is also available on One Energy’s Investor Relations site: https://oneenergy.com/investors/

Jereme Kent, CEO of One Energy, said, “From its inception, the electric semi-industry had an obvious chicken and egg problem. Truck manufacturers and fleet operators need to be able to charge at scale before they can move forward with deploying electric trucks at scale. This Megawatt Hub configuration solves that problem. The power is already on-site, at the right voltage, and we can outfit and energize custom Power Island™ configurations with the necessary charging equipment in weeks or months, not years.”

The electric semi-truck manufacturing industry has stated that a serious impediment to customer adoption of electric fleets has been getting enough power at the correct voltage from the grid to allow customers to connect their chargers. One Energy designed this site to solve that problem by delivering charger-ready power at scale. A 138,000-volt transmission line serves the Findlay Megawatt Hub. One Energy’s facility has the capacity to charge 90 trucks concurrently (based on a typical 300-kW charge rate). The company expects to obtain direct access to transmission service pricing to provide some of the lowest-cost energy available in the United States. In addition, the site design allows it to host behind-the-meter renewable energy generation from wind and solar as demand at the site matures.

Dana Saucier, Head of Economic Development for JobsOhio, said, “Ohio has proudly led the charge in manufacturing and logistics for over a century and we’re positioned to lead for another century with pioneering projects like One Energy’s new electric semi-truck charging site in Findlay. Our state boasts some of the most competitive power costs in the world and a robust high-voltage transmission infrastructure. Unlike some states, we don’t need to wait years or rely on mandates and subsidies to advance the electrification of logistics. This site is a testament to that fact. Simply put, Ohio is fast becoming the Silicon Valley of energy innovation.”

The Findlay Megawatt Hub was built by One Energy with its own capital and without government subsidies or grants. One Energy received no utility incentives for the site. Thomas Lause, CFO of One Energy, explained, “Capital markets are good at building the second and third projects after the pilot has proven successful, but they have always struggled with underwriting the first one. Because we are confident in the solution and the technology, we decided not to wait. We just built it. Now we have a functioning site to show capital markets.”

Kent concluded, “We are throwing down a gauntlet to jumpstart the electric semi-industry. We have already built full-scale, cost-effective charging that can serve multiple end-users. We have done it in the manufacturing center of the United States, where there are numerous local and regional truck routes. Now we are excited to see the electric semi manufacturers deliver.”

The Megawatt Hub by the Numbers:

  • 30 megawatts = 30,000 kilowatts

  • 90 x 300kW chargers concurrently or 30 x 1 MW chargers concurrently

  • 720,000 kilowatt hours a day of capacity

  • Up to 1,000 x 500kWh battery charges a day

About One Energy (One Power)

One Energy is an industrial power company and the largest installer of on-site, behind-the-meter, wind energy in the United States. Recognizing that large energy consumers are fed up with the failings of legacy utilities, One Energy developed modern energy services to control cost and risk, such as Wind for Industry® and Managed High Voltage®. One Energy is building the customer-centric grid of the future. Founded in 2009, One Energy is headquartered in Findlay, Ohio. Learn more about the customer-centric power grid of the future at One Energy’s website (www.oneenergy.com).

On August 15, 2023, One Energy Enterprises Inc. and TortoiseEcofin Acquisition Corp. III (NYSE: “TRTL”) announced that they have entered into a definitive Business Combination Agreement for a business combination that is intended to result in the combined Company, One Power Company, being listed on the New York Stock Exchange under the ticker symbol “ONEP”.

Additional Information and Where to Find It

In connection with the proposed transaction (the “Proposed Transaction”) between TortoiseEcofin Acquisition Corp. III (“TRTL”) and One Energy Enterprises Inc. (“One Energy,” the business of which (referred to herein as “One Power”), after consummation, if any (the “Closing”) of the Proposed Transaction, will be the business of the “Combined Company,” which is expected to be renamed “One Power Company”), which is the subject of the Agreement and Plan of Merger between TRTL, One Energy and certain other parties thereto (the “Merger Agreement”), TRTL intends to file a registration statement on Form S-4 (as may be amended or supplemented from time to time, the “Form S-4” or the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”), which will include a preliminary proxy statement and a prospectus in connection with the Proposed Transaction. SHAREHOLDERS OF TRTL ARE ADVISED TO READ, WHEN AVAILABLE, THE PRELIMINARY PROXY STATEMENT, ANY AMENDMENTS THERETO, THE DEFINITIVE PROXY STATEMENT, THE PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. HOWEVER, THIS DOCUMENT WILL NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION. IT IS ALSO NOT INTENDED TO FORM THE BASIS OF ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF THE PROPOSED TRANSACTION. When available, the definitive proxy statement and other relevant documents will be mailed to the shareholders of TRTL as of a record date to be established for voting on the Proposed Transaction. Shareholders and other interested persons will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, the Registration Statement and other documents filed by TRTL with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov.

TRTL’s shareholders will also be able to obtain a copy of such documents, without charge, by directing a request to: TortoiseEcofin Acquisition Corp. III, 195 US HWY 50, Suite 208, Zephyr Cove, NV 89448; e-mail: [email protected]. These documents, once available, can also be obtained, without charge, at the SEC’s website at www.sec.gov.

Participants in the Solicitation

TRTL, One Energy and their respective directors and executive officers may be deemed participants in the solicitation of proxies of TRTL’s shareholders in connection with the Proposed Transaction. TRTL’s shareholders and other interested persons may obtain more detailed information regarding the names, affiliations and interests of certain of TRTL executive officers and directors in the solicitation by reading TRTL’s final prospectus filed with the SEC on July 21, 2021, in connection with TRTL’s initial public offering, TRTL’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 24, 2022, TRTL’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 22, 2023, and TRTL’s other filings with the SEC. A list of the names of such directors and executive officers and information regarding their interests in the Proposed Transaction, which may, in some cases, be different from those of shareholders generally, will be set forth in the Registration Statement relating to the Proposed Transaction when it becomes available. These documents can be obtained free of charge from the source indicated above.

No Offer or Solicitation

This communication shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Proposed Transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act or an exemption therefrom.

Forward-Looking Statements

This communication may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein are forward-looking statements. Such forward-looking statements include, but are not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding One Power, the Combined Company and the Proposed Transaction and the future held by the respective management teams of TRTL or One Power, the anticipated benefits and the anticipated timing of the Proposed Transaction, future financial condition and performance of One Power or the Combined Company)and expected financial impacts of the Proposed Transaction (including future revenue, profits, proceeds, pro forma enterprise value and cash balance), the satisfaction of closing conditions to the Proposed Transaction, financing transactions, if any, related to the Proposed Transaction, the level of redemptions by TRTL’s public shareholders and the expected future performance and market opportunities of One Power or the Combined Company. These forward-looking statements generally are identified by the words “anticipate,” “believe,” “could,” “expect,” “estimate,” “future,” “intend,” “may,” “might,” “strategy,” “opportunity,” “plan,” “project,” “possible,” “potential,” “project,” “predict,” “scales,” “representative of,” “valuation,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including, without limitation: (i) the risk that the Proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of TRTL’s securities, (ii) the risk that the Proposed Transaction may not be completed by TRTL’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by TRTL, (iii) the failure to satisfy the conditions to the consummation of the Proposed Transaction, including the requirements that the Merger Agreement and the transactions contemplated thereby be approved by the shareholders of TRTL and by the stockholders of One Energy, respectively, (iv) the failure to obtain regulatory approvals and any other third party consents, as applicable, as may be required to consummate the Proposed Transaction, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, or that redemptions by TRTL public shareholders may exceed expectations, (vi) the effect of the announcement or pendency of the Proposed Transaction on One Power’s business relationships, operating results, and business generally, (vii) risks that the Proposed Transaction disrupts current plans and operations of One Power, (viii) the outcome of any legal proceedings that may be instituted against One Energy or against TRTL related to the Merger Agreement or the Proposed Transaction, (ix) the ability to maintain the listing of TRTL’s securities on NYSE, (x) changes in the competitive market in which One Power operates, variations in performance across competitors, changes in laws and regulations affecting One Power’s business and changes in the capital structure of the Combined Company after the Closing, (xi) the ability to implement business plans, growth, marketplace, customer pipeline and other expectations after the completion of the Proposed Transaction, and identify and realize additional opportunities, (xiii) the potential inability of One Power to achieve its business and growth plans, (xiv) the ability of One Power to enforce its current material contracts or to secure long-term or other committed contracts with new or existing customers on terms favorable to One Power, (xv) the risk that One Power will need to raise additional capital to execute its business plans, which may not be available on acceptable terms or at all; (xvi) the risk that One Power experiences difficulties in managing its growth and expanding operations; (xvii) the risk of our cyber security measures being unable to prevent hacking or disruption to our customers; and (xviii) the risk of economic downturn, increased competition, a changing of energy regulatory landscape and related impacts that could occur in the highly competitive energy market, including, among other things, that One Power will not meet milestones for funding its ongoing and future project pipeline. The foregoing list of factors is not exhaustive. Recipients should carefully consider such factors and the other risks and uncertainties described and to be described in the “Risk Factors” section of TRTL’s initial public offering prospectus filed with the SEC on July 21, 2021, TRTL’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 24, 2022, TRTL’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 22, 2023, and subsequent periodic reports filed by TRTL with the SEC, the Registration Statement to be filed by TRTL in connection with the Proposed Transaction and other documents filed or to be filed by TRTL from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Recipients are cautioned not to put undue reliance on forward-looking statements, and neither One Energy nor TRTL assume any obligation to, nor intend to, update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Neither One Energy nor TRTL gives any assurance that either One Energy or TRTL, or the Combined Company, will achieve its expectations.

Information Sources; No Representations

The communication furnished herewith has been prepared for use by TRTL and One Power in connection with the Proposed Transaction. The information therein does not purport to be all-inclusive. The information therein is derived from various internal and external sources, with all information relating to the business, past performance, results of operations and financial condition of TRTL derived entirely from TRTL and all information relating to the business, past performance, results of operations and financial condition of One Power, or the Combined Company after the Closing, are derived entirely from One Energy (referred to herein as “One Power”). No representation is made as to the reasonableness of the assumptions made with respect to the information therein, or to the accuracy or completeness of any projections or modeling or any other information contained therein. Any data on past performance or modeling contained therein is not an indication as to future performance.

No representations or warranties, express or implied, are given in respect of the communication. To the fullest extent permitted by law in no circumstances will TRTL or One Energy, or any of their respective subsidiaries, affiliates, shareholders, representatives, partners, directors, officers, employees, advisors or agents, be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of the this communication (including without limitation any projections or models), any omissions, reliance on information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith, which information relating in any way to the operations of One Energy or the prospective operations of One Power has been derived, directly or indirectly, exclusively from One Energy and has not been independently verified by TRTL or any other party. Neither the independent auditors of TRTL nor the independent auditors of or One Energy audited, reviewed, compiled or performed any procedures with respect to any projections or models for the purpose of their inclusion in the communication and, accordingly, neither of them expressed any opinion or provided any other form of assurances with respect thereto for the purposes of the communication.

For Investors:

John Ragozzino, CFA

ICR, Inc.

[email protected]

For Media:

Matt Dallas

ICR, Inc.

[email protected]

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Alternative Vehicles/Fuels Trucking EV/Electric Vehicles Automotive General Automotive Transport Utilities Alternative Energy Energy Fleet Management

MEDIA:

Photo
Photo
One Energy’s Megawatt Hub can deliver 760,000 kWh of capacity, powering up to 90 electric semi-trucks per day (Photo: Business Wire)
Photo
Photo
One Energy’s Megawatt Hub can serve thousands of electric semi-trucks (Photo: Business Wire)
Photo
Photo
One Energy’s customizable Power Island™ charging configurations (Photo: Business Wire)